Form 4: ResMed CFO Exercises Options, Sells Shares

ResMed Inc.'s Chief Financial Officer, Brett Sandercock, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

Summary

• Brett Sandercock, Chief Financial Officer of ResMed Inc. (RMD), reported transactions on November 3, 2025.
• Sandercock acquired 2,000 shares of ResMed Common Stock by exercising options at a price of $101.64 per share, totaling $203,280.
• Following the option exercise, his direct beneficial ownership was 88,745 shares.
• He then disposed of 3,000 shares of ResMed Common Stock at a price of $247.54 per share, totaling $742,620.
• After these transactions, his direct beneficial ownership stands at 85,745 shares.
• Both transactions were conducted pursuant to a Rule 10b5-1 plan adopted on February 19, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction executed under a pre-arranged 10b5-1 plan, which typically does not reflect a change in management's immediate outlook on the company's prospects.

Positives

• The CFO realized a gain by exercising options at a strike price of $101.64 and selling shares at a market price of $247.54, indicating a profitable transaction for the insider.
• The transactions were executed under a Rule 10b5-1 plan, which demonstrates pre-planned, non-discretionary trading and can mitigate concerns about opportunistic insider trading.

Negatives

• The net effect of the transactions was a reduction of 1,000 shares in the CFO's direct beneficial ownership of ResMed Common Stock (2,000 acquired 3,000 disposed).

Future Outlook

This Form 4 filing reports past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction by a key executive and does not provide information directly related to broader industry trends or competitive landscape. Such transactions are common for executives managing their equity compensation.

Stakeholder Impact

• Shareholders: The transaction represents a minor reduction in direct insider ownership, which is a common occurrence for executives managing their compensation and liquidity. Given it's under a 10b5-1 plan, it's unlikely to signal a change in management's confidence.

Key Dates

Keywords

RMD, ResMed, Form 4, Insider Trading, Stock Options, CFO, Share Sale, 10b5-1 Plan